This report presents data on national estimates of substance-related ED visits from 60 participating DAWN hospitals in 2024. The data includes (1) all drug-related ED visits, (2) the top substances involved in drug-related ED visits, (3) opioid-related ED visits by type, and (4) polysubstance-related ED visits.

An analysis of the 2022 DAWN data presents:(1) nationally representative weighted estimates of all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; (3) nationally representative weighted estimates of opioid-related ED visits by type of opioid, (4) drugs involved in polysubstance ED visits, and (5) the identification of newly mentioned drugs in 2022.Clickhereto view the 2022 report.

An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related ED visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (4) the identification of drugs new to DAWN’s Drug Reference Vocabulary.Clickhereto view the 2021 final report.

Drug Abuse Warning Network (DAWN): Drug-Related ED Visits Involving Suicide Attempts Short Report presents (1) national estimates and characteristics of drug-related ED visits involving suicide attempts and (2) the top substance involved in suicide attempts.

Includes the annual report with national estimates of drug-related visits to hospital emergency departments (EDs) for 2011, based on data from the Drug Abuse Warning Network (DAWN); the methodology report, updated for 2011; a glossary of terms updated for 2011, and a guide to the DAWN trend tables (data tables).

This report presents data from DAWN to describe national estimates of polysubstance-involved emergency department (ED) visits in the United States in 2024. It provides estimates of polysubstance-involved ED visits by (1) patient characteristics, (2) psychoactive drug involved, and (3) co-occurrence (or combination) of psychoactive drugs.

Includes the annual report with national estimates of drug-related visits to hospital emergency departments (EDs) for 2010, based on data from the Drug Abuse Warning Network (DAWN); the methodology report, updated for 2010; a glossary of terms updated for 2010, and a guide to the DAWN ED trend tables (data tables). .

This Drug Abuse Warning Network (DAWN) short report summarizes key findings about drug-related emergency department visits between 2004 and 2011. The report includes data for illicit drugs, alcohol, and prescription and over-the counter medications. For medications, the report looks at misuse and abuse, adverse reactions, and accidental ingestion of drugs by children.

This publication describes the methodologies used by the Drug Abuse Warning Network (DAWN), to collect, prepare, and analyze information on drug-related emergency department (ED) visits in the United States. The methods described here were initiated in 2004 and are current as of 2010.

,The Drug Abuse Warning Network (DAWN) survey is designed to capture data on emergency department (ED) episodes that are induced by or related to the use of an illicit, prescription, or over-the-counter drug. For purposes of this collection, a drug "episode" is an ED visit that was induced by or related to the use of an illegal drug or the nonmedical use of a legal drug for patients aged six years and older. A drug "mention" refers to a substance that was mentioned during a drug-related ED episode. Because up to four drugs can be reported for each drug abuse episode, there are more mentions than episodes in the data. Individual persons may also be included more than once in the data. Within each facility participating in DAWN, a designated reporter, usually a member of the emergency department or medical records staff, was responsible for identifying drug-related episodes and recording and submitting data on each case. An episode report was submitted for each patient visiting a DAWN emergency department whose presenting problem(s) was/were related to their own drug use. DAWN produces estimates of drug-related emergency department visits for 50 specific drugs, drug categories, or combinations of drugs, including the following: acetaminophen, alcohol in combination with other drugs, alprazolam, amitriptyline, amphetamines, aspirin, cocaine, codeine, diazepam, diphenhydramine, fluoxetine, heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam, marijuana/hashish, methadone, methamphetamine, and PCP/PCP in combination with other drugs. The use of alcohol alone is not reported. The route of administration and form of drug used (e.g., powder, tablet, liquid) are included for each drug. Data collected for DAWN also include drug use motive and total drug mentions in the episode, as well as race, age, patient disposition, reason for ED visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.,